Usefulness and limitations of E-cadherin and β-catenin in the classification of breast carcinomas in situ with mixed pattern.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Gomes DS;Gomes DS; Porto SS; Rocha RM; Gobbi H
  • Source:
    Diagnostic pathology [Diagn Pathol] 2013 Jul 09; Vol. 8, pp. 114. Date of Electronic Publication: 2013 Jul 09.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101251558 Publication Model: Electronic Cited Medium: Internet ISSN: 1746-1596 (Electronic) Linking ISSN: 17461596 NLM ISO Abbreviation: Diagn Pathol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, 2006-
    • Subject Terms:
      Immunohistochemistry* ; Neoplasms, Complex and Mixed*; Biomarkers, Tumor/*analysis ; Breast Neoplasms/*chemistry ; Cadherins/*analysis ; Carcinoma in Situ/*chemistry ; Carcinoma, Ductal, Breast/*chemistry ; Carcinoma, Lobular/*chemistry ; beta Catenin/*analysis; Adult ; Antigens, CD ; Breast Neoplasms/classification ; Breast Neoplasms/pathology ; Carcinoma in Situ/classification ; Carcinoma in Situ/pathology ; Carcinoma, Ductal, Breast/classification ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Lobular/classification ; Carcinoma, Lobular/pathology ; Female ; Humans ; Immunophenotyping ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Retrospective Studies
    • Abstract:
      Background: The distinction between lobular neoplasia of the breast and ductal carcinoma in situ has important therapeutic implications. In some cases, it is very difficult to determine whether the morphology of the lesion is ductal or lobular. The aim of this study was to evaluate the value of E-cadherin and β-catenin expression through the immunophenotypical characterization of carcinoma in situ with mixed pattern (CISM).
      Methods: A total of 25 cases of CISM were analyzed considering cytology/mixed architecture (ductal and lobular), nuclear pleomorphism, loss of cell cohesion, and presence of comedonecrosis. The immunophenotype pattern was considered E-cadherin positive and β-catenin positive, or negative.
      Results: Nineteen (76%) cases presented a mixed cytology and / or architectural pattern, two (8%) presented nuclear pleomorphism, two (8%) presented mixed cytology and nuclear pleomorphism, and two (8%) presented comedonecrosis and nuclear pleomorphism. A complete positivity for E-cadherin and β-catenin was observed in 11 cases (44%). In one case, the lesion was negative for both markers and showed nuclear pleomorphis. Thirteen lesions showed negative staining in areas of lobular cytology and positive staining in cells presenting the ductal pattern.
      Conclusions: The expression of E-cadherin and β-catenin, combined with cytological and architectural analysis, may highlight different immunophenotypes and improve classification of CISM.
      Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/ 1693384202970681
    • References:
      Radiol Clin North Am. 2000 Jul;38(4):791-807. (PMID: 10943278)
      Diagn Pathol. 2011 Nov 04;6:109. (PMID: 22053859)
      Breast Cancer Res. 2012 Feb 08;14(1):203. (PMID: 22315958)
      Diagn Pathol. 2011 Aug 09;6:74. (PMID: 21827679)
      Semin Diagn Pathol. 1999 Aug;16(3):209-23. (PMID: 10490198)
      Am J Clin Pathol. 2001 Jan;115(1):85-98. (PMID: 11190811)
      Am J Surg Pathol. 2001 Feb;25(2):237-44. (PMID: 11176073)
      Anticancer Res. 2008 Nov-Dec;28(6A):3815-26. (PMID: 19189669)
      Hum Pathol. 2002 Jun;33(6):620-7. (PMID: 12152161)
      Cancer. 2008 May 15;112(10):2152-8. (PMID: 18348299)
      Diagn Pathol. 2013 Jan 21;8:10. (PMID: 23337059)
      Eur J Cancer. 2006 Sep;42(14):2205-11. (PMID: 16876991)
      J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. (PMID: 9747868)
      Am J Surg Pathol. 2001 Feb;25(2):229-36. (PMID: 11176072)
      Am J Surg Pathol. 2008 May;32(5):773-83. (PMID: 18379416)
      Oncogene. 2004 Apr 22;23(19):3272-83. (PMID: 15077190)
      Cancer. 2001 Aug 15;92(4):738-47. (PMID: 11550142)
      Am J Surg Pathol. 2007 Mar;31(3):427-37. (PMID: 17325485)
      Biochem Biophys Res Commun. 2009 Jun 19;384(1):6-11. (PMID: 19379710)
      Am J Clin Pathol. 2001 Apr;115(4):534-42. (PMID: 11293901)
      Mod Pathol. 2008 Oct;21(10):1224-37. (PMID: 18587329)
    • Accession Number:
      0 (Antigens, CD)
      0 (Biomarkers, Tumor)
      0 (CDH1 protein, human)
      0 (CTNNB1 protein, human)
      0 (Cadherins)
      0 (beta Catenin)
    • Publication Date:
      Date Created: 20130711 Date Completed: 20140929 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      PMC3772705
    • Accession Number:
      10.1186/1746-1596-8-114
    • Accession Number:
      23837653